Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, Radj Gervais, José Luis Perez‐Gracia, Ji‐Youn Han, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Matthew A. Gubens, Michael Boyer, Wu‐Chou Su, Ayman Samkari, Erin Jensen, Julie Kobie, Bilal Piperdi, Paul Baas
Topics & Concepts
PembrolizumabDocetaxelMedicineInternal medicineHazard ratioConfidence intervalOncologySurgeryChemotherapyCancerImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentEsophageal Cancer Research and Treatment